UTMD Q2 2026 revenue down 14.3% to $8.5M; EPS $0.844 vs $0.939; cuts FY2026 guidance to -10-13% decline

UTAH MEDICAL PRODUCTS INC

Q2 2026 revenue $8.53M, down 14.3% from $9.95M in Q2 2025; 1H revenue $17.25M, down 12.3%.
Diluted EPS $0.844 in Q2 2026 vs $0.939 in Q2 2025, a 10.1% decline; 1H EPS $1.661 vs $1.858.
FY2026 revenue guidance cut to decline of 10-13% from prior expectation of flat; new product sales slower than expected.
Litigation costs in 1H 2026 were $1.3M vs $1.0M in 1H 2025; now expects 2026 litigation <$1.6M vs prior <$1.355M.
Cash and investments $87.5M, no debt; share repurchases minimal at $0.2M in 1H 2026 vs $6.7M in 1H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.